Sarcoma Research Grant Program

Research

The ANZSA’s Consumer Advisory Panel (CAP) was formed to give a strong voice to consumers within the sarcoma community, as it recognises the value and importance of consumer input in sarcoma clinical trials.<\/p>\r\n\r\n

Chaired by ANZSA Board Director, Sarah Cheung, the CAP plays an integral role in supporting, mentoring, advocating and training to the sarcoma community through its committee and consumer advocates.<\/p>\r\n\r\n

Key responsibilities of ANZSA’s CAP include:<\/p>\r\n\r\n

Assessing the relevance of new clinical trial concepts and protocols under the consideration of the ANZSA’s SAC.<\/li>\r\n\t
Reviewing Patient Information Sheet and Consent Forms.<\/li>\r\n\t
Advising on patient recruitment strategies.<\/li>\r\n\t
Increasing the awareness of ANZSA and sarcoma research.<\/li>\r\n\t
Advocating for sarcoma research funding.<\/li>\r\n<\/ul>","status":"active","position":"4","is_deleted":"false","created_at":"2021-06-18 10:33:38","updated_at":"2024-01-10 14:20:39"},{"id":3,"name":"Sarcoma Research Grant Program","slug":"sarcoma-research-grant-program","description":"
Every year, ANZSA is proud to fund Australian researchers through its Sarcoma Research Grant Program with the aim to improve early diagnosis, treatment options, outcomes and quality of life for sarcoma patients.<\/p>\r\n\r\n
Since the formalisation of the ANZSA Sarcoma Research Grant Program in 2011, the organisation has awarded more than 30 local researchers with grants worth over $1.2 million.<\/p>\r\n\r\n
The ANZSA Sarcoma Research Grant Program is funded by generous sarcoma charitable foundations that were established by friends and families.<\/p>\r\n\r\n
Upon realising the challenges in sarcoma research and treatment due to resources and awareness, these foundations decided to make a difference for future sarcoma patients through fundraising campaigns.<\/p>\r\n\r\n
Apply now for our 2025 Research Grants<\/a><\/strong><\/span><\/p>\r\n\r\n
<\/p>","status":"active","position":"3","is_deleted":"false","created_at":"2019-05-24 10:06:24","updated_at":"2025-02-10 15:20:51"},{"id":2,"name":"Scientific Advisory Committee","slug":"scientific-advisory-committee","description":"
Co-chaired by ANZSA Directors, Prof Angela Hong and A\/Prof Jayesh Desai, the main priority of the Scientific Advisory Committee (SAC) is to oversee all of ANZSA’s clinical trial programs, translational research studies, and other sarcoma research activities.<\/p>\r\n\r\n
Our SAC is responsible for:<\/p>\r\n\r\n

Sarcoma Research Grant Program

Every year, ANZSA is proud to fund Australian researchers through its Sarcoma Research Grant Program with the aim to improve early diagnosis, treatment options, outcomes and quality of life for sarcoma patients.

Since the formalisation of the ANZSA Sarcoma Research Grant Program in 2011, the organisation has awarded more than 30 local researchers with grants worth over $1.2 million.

The ANZSA Sarcoma Research Grant Program is funded by generous sarcoma charitable foundations that were established by friends and families.

Upon realising the challenges in sarcoma research and treatment due to resources and awareness, these foundations decided to make a difference for future sarcoma patients through fundraising campaigns.

Apply now for our 2025 Research Grants

ANZSA Research Grant

ANZSA Research Grant

2021 | Fernando Guimaraes | The University of Queensland | $40,000

Development of a natural killer cell-based immunotherapy for Rhabdomyosarcoma

2021 | Vijesh Vaghjiani | Hudson Institue of Medical Research | $40,000

Targeting oncogenic drivers in therapy resistant osteosarcoma

2022 | Elizabeth Connolly | Chris O'Brien Lifehouse | $40,000

MYTH Study: Methotrexate for AYAs in the home for AYA osteosarcoma patients. A study of safety, feasibility, patient acceptability and cost effectiveness of an ambulatory model

2022 | Sarat Chander | Peter MacCallum Cancer Centre | $25,000

Spatially Fractionated Radiation Therapy for Inoperable or Metastatic Sarcoma

2023 | Ian Parish | Peter MacCallum Cancer Centre | $40,000

Investiagting the ro;e of CD8+ T cell tolerance within the tunour draining lymph node in immune evasion by retroperitoneal sarcoma

2023 | Angela Hong | Royal Prince Alfred Hospital and Chris O'Brien Lifehouse | $15,000

Radiotherapy Quality Assurance for the Prospective study evaluating the treatment outcomes for localised recurrent, resectable retroperitoneal liposarcoma

GPA Andrew Ursini Sarcoma Research Grant

GPA Andrew Ursini Sarcoma Research Grant

2012 | Jason Cain | Monash | $50,000

Investigating the effect of the histone deacetylase inhibitor, LBH589, on chemotherapy sensitisation and residual disease in pre-clinical models of osteosarcoma

2013 | Jason Cain | Monash | $50,000

Investigating the effect of the histone deacetylase inhibitor, LBH589, on chemotherapy sensitisation and residual disease in pre-clinical models of osteosarcoma

2013-2014 | Susan Neuhaus | Royal Adelaide Hospital | $50,000

Improving outcomes in curable sarcoma

2016 | Christine Hawkins | La Trobe University | $75,000 (over 3 years)

Testing the efficacy and safety of SM-164 for osteosarcoma treatment

Hannah’s Chance Foundation Sarcoma Research Grant

Hannah’s Chance Foundation Sarcoma Research Grant

2013 | Brendan Joss | Hollywood Private Hospital (WA) | $30,000

A multidisciplinary team approach to improving long term outcomes in sarcoma survivors

2017 | Hayden Snow | Peter MacCallum Cancer Centre | $30,000

Characterising the immune microenvironment in adipocytic and non-adipocytic sarcoma, its impact on prognosis and the effect of radiotherapy

2018 | Jeremy Lewin | Peter MacCallum Cancer Centre | $30,000

Applying radiomics to predict outcomes in patients with high grade retroperitoneal sarcoma treated with preoperative radiotherapy

2019 | Cristina Vargas | Douglass Hanly Moir Pathology, Sonic, and University of Sydney | $40,000

Metastatic and recurrent soft tissue sarcomas – investigation of DNA methylation changes and their contribution to sarcoma progression

Johanna Sewell Sarcoma Research Grant

Johanna Sewell Sarcoma Research Grant

2011 | Kate McBride | University of Sydney | $50,000

To map p53 pathway mutations in Australian Sarcoma Kindred Study index cases and examine the relationship with outcomes in these patients

2012 | Mary-Anne Young | Peter MacCallum Cancer Centre | $25,000

Research participants’ and healthcare professionals’ views of the feedback of genetic test information following participation in the International Sarcoma Kindred study (ISKS)

2013 | Gillian Mitchell | Peter MacCallum Cancer Centre | $50,000

A pilot surveillance study in Li Fraumeni syndrome

2013 | Damian Myers | St Vincents Melbourne | $25,000

‘Quantum Dots’ with combined structural and functional imaging to investigate osteosarcoma biology and potential therapies.

2014 | Daniel Gough | Monash Institute of Medical Research | $50,000

Defining the role of STAT3 as a tumour suppressor in osteosarcoma

2015 | David Goode | Peter MacCallum Cancer Centre | $50,000

Validating putative novel sarcoma risk genes via targeted DNA sequencing

2016 | Jeremy Hensen | University of New South Wales | $50,000

New drug combination with ATR-CHK1 axis inhibitors for osteosarcoma

2017 | Lucy Coupland | John Curtin School of Medical Research | $50,000

Novel therapies for osteosarcoma: RNA Pol I inhibitors

2018 | Anneke Blackburn | Australian National University | $50,000

Dichloroacetate (DCA) in Osteosarcoma: A non-toxic agent targeting cancer metabolism

2019 | Willem Joost Lesterhuis | Telethon Kids Institute, Centre for Child Health Research, University of Western Australia | $50,000

Local peri-operative immunotherapy for soft tissue sarcoma

2020 | James Blackburn | Garvan Institute of Medical Research | $50,000

Improving fusion gene detection and immune response assessment in sarcoma patients

Leon Stone Sarcoma Research Grant

Leon Stone Sarcoma Research Grant

2013 | Mannu Walia | St Vincents | $34,000

Deciphering the role of cAMP response element binding protein (CREB) in osteosarcoma

2014 | Liliana Endo-Munoz | Diamantina Institute, University of Queensland | $36,000

Defining the role of STAT3 as a tumour suppressor in osteosarcoma

2015 | Christine Hawkins | La Trobe University | $25,000

Pre-clinical evaluation of IAP antagonists in osteosarcoma

2016 | Kenneth Hsu | The Kids Research Institute, The Children’s Hospital at Westmead | $20,000

Developing genetically modified T-cells for the treatment of paediatric tumours

2018 | Jonathan Karpelowsky | Judging a cell by its cover – osteosarcoma circulating tumour cells testing | $20,000

Judging a cell by its cover – osteosarcoma circulating tumour cells testing

2019 | Belinda Kramer | The Kids Research Institute, The Children’s Hospital at Westmead | $20,000

Mass cytometry to characterise sarcoma targeted CAR T cells and inform clinical trial design

Rainbows for Kate Sarcoma Research Grant

Rainbows for Kate Sarcoma Research Grant

2011-2013 | Kathleen Pishas | University of Adelaide | $25,000 (pa)

Treatment of Ewing sarcoma family of tumours through the pharmacological activation of p53

2013-2015 | Xiaochun Wang | University of New South Wales | $25,000 (pa)

Multiple targeted therapies in human sarcomas

2023 | Minh-Son To | Flinders University | $40,000

Improving the radiological evaluation of bone and soft tissue sarcomas with advanced diffusion imaging and artificial intelligence

Xavier Krikori Sarcoma Research Grant

Xavier Krikori Sarcoma Research Grant

2011 | Damien Myers | St Vincents Melbourne | $25,000

Suppression of osteosarcoma tumour invasion and metastasis: Monitoring therapeutic outcomes using advanced imaging techniques

2014 | Katheen Pishas | Hanson Institute, University of Adelaide | $20,000

Exploiting a novel therapeutic target in Ewing sarcoma

2014 | Katheen Pishas | Hanson Institute, University of Adelaide | $20,000

Dedifferentiation of MDM2 amplified low-grade liposarcoma: Comparative genomics and transcriptomics to determine the mechanisms of tumour progression and precision targets

2016 | Timothy Chittleborough | Peter MacCallum Cancer Centre | $20,000

Profiling desmoid tumours in FAP patients and exploring new strategies to prevent and treat desmoid tumours using a novel mouse model

2017 | Toby Trahair | Kids Cancer Centre, Sydney Children's Hospital | $26,000

New therapies for ALK-rearranged inflammatory myofibroblastic tumour (IMT) and epithelioid inflammatory myofibroblastic sarcoma (eIMS)

2018 | Federica Saletta | The Children’s Hospital at Westmead | $20,000

Development of liquid biopsy assays to test minimal residual disease in Ewing sarcoma and alveolar rhabdomyosarcoma patients

2019 | Evan Ingley | Harry Perkins Institute of Medical Research | $20,000

Exploiting a novel therapeutic target in Ewing sarcoma

2020 | Rachael Terry | Children’s Cancer Institute | $40,000

New immunotherapy strategies for paediatric rhabdomyosarcomas

2023 | Carolyn Shembrey | Peter MacCallum Cancer Centre | $40,000

Harnessing CRISPR-Cas13 to ablate 'undruggable' sarcoma drivers

Formerly known as the Australasian
Sarcoma Study Group and the Australian
Sarcoma Group

Australia and New Zealand Sarcoma Association
VCCC
Level 1
305 Grattan Street
Melbourne Victoria 3000
Australia

T +61 437 880 835
E contact@sarcoma.org.au

The Australia and New Zealand
Sarcoma Association is registered
as a charity with the Australian
Charities and Not-for-profits
Commission ABN 73 132 759 525

© 2025 All rights reserved | ANZSA receives funding from the Australian Government through Cancer Australia | Terms & Conditions | Privacy Policy | Contact | Website by Echo3